Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Chih-Yuan Chuang, Scott E. Collibee, Luke Ashcraft, Wenyue Wang, Mark Vander Wal, Xiaolin Wang, Darren T. Hwee, Yangsong Wu, Jingying Wang, Eva R. Chin, Peadar Cremin, Jeanelle Zamora, James J. Hartman, Julia Schaletzky, Eddie Wehri, Laura Robertson, Fady I. Malik, B. Paul Morgan
Abstract
similar to predictions and was able to reach steady state concentration within the desired two-week window.
Topics & Concepts
Hypertrophic cardiomyopathyChemistryPharmacologyPharmacokineticsPharmacodynamicsIn vivoDrug discoverySarcomereTherapeutic windowCardiologyInternal medicineMyocyteMedicineBiochemistryBiologyBiotechnologyCardiomyopathy and Myosin StudiesViral Infections and Immunology ResearchTrypanosoma species research and implications